Compare Hemas Holdings Plc with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
LKR 101,483 Million (Large Cap)
12.00
NA
0.00%
-0.00
16.59%
1.91
Revenue and Profits:
Net Sales:
35,009 Million
(Quarterly Results - Dec 2025)
Net Profit:
2,744 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-72.09%
0%
-72.09%
6 Months
-63.01%
0%
-63.01%
1 Year
-61.22%
0%
-61.22%
2 Years
-48.55%
0%
-48.55%
3 Years
-26.74%
0%
-26.74%
4 Years
-59.88%
0%
-59.88%
5 Years
-43.46%
0%
-43.46%
Hemas Holdings Plc for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
15.00%
EBIT Growth (5y)
20.53%
EBIT to Interest (avg)
6.95
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
-0.13
Sales to Capital Employed (avg)
2.05
Tax Ratio
35.76%
Dividend Payout Ratio
33.36%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
24.07%
ROE (avg)
14.05%
Valuation key factors
Factor
Value
P/E Ratio
12
Industry P/E
Price to Book Value
2.18
EV to EBIT
8.23
EV to EBITDA
7.03
EV to Capital Employed
2.31
EV to Sales
0.84
PEG Ratio
NA
Dividend Yield
0.06%
ROCE (Latest)
28.02%
ROE (Latest)
17.59%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Sideways
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
35,009.00
32,286.90
8.43%
Operating Profit (PBDIT) excl Other Income
4,615.30
3,957.70
16.62%
Interest
235.20
186.20
26.32%
Exceptional Items
0.00
0.00
Consolidate Net Profit
2,743.90
2,160.40
27.01%
Operating Profit Margin (Excl OI)
115.00%
104.80%
1.02%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is 8.43% vs 13.18% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is 27.01% vs 72.10% in Sep 2025
Annual Results Snapshot (Consolidated) - Mar'25
Mar'25
Mar'24
Change(%)
Net Sales
117,970.20
121,613.80
-3.00%
Operating Profit (PBDIT) excl Other Income
14,160.30
12,756.40
11.01%
Interest
1,500.40
3,254.60
-53.90%
Exceptional Items
336.20
265.00
26.87%
Consolidate Net Profit
8,338.70
6,354.70
31.22%
Operating Profit Margin (Excl OI)
103.10%
91.10%
1.20%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2025 is -3.00% vs 6.74% in Mar 2024
Consolidated Net Profit
YoY Growth in year ended Mar 2025 is 31.22% vs 25.37% in Mar 2024
About Hemas Holdings Plc 
Hemas Holdings Plc
Pharmaceuticals & Biotechnology
Hemas Holdings PLC (Hemas) is a Sri Lanka-based pharmaceuticals company engaged in healthcare, leisure and transportation services. The Company operates in various segments, such as FMCG, Healthcare, Leisure, Transportation, Power and others. The FMCG business sector manufactures and markets personal care and home care branded products. Its Healthcare sector is a distributor of pharmaceuticals, surgical and diagnostic products in Sri Lanka. Its Leisure sector consists of the Serendib Leisure Group of Hotels. The Transportation sector consists of the aviation business both in the passenger and cargo segments, its maritime business providing feeder operations and agency services for international shipping partners, its outbound travel agency services via Hemas Travels and its logistics business unit consists of integrated logistic services.
Company Coordinates 
Company Details
No 75, Braybrooke Place, Colombo 02 , COLOMBO None : 01
Registrar Details






